MedWatch

Analyst: Chinese reforms will impact sales and earnings at Novo Nordisk

Chinese healthcare reforms, meant to reduce healthcare expenses, could negatively affect Novo Nordisk, assesses Jyske Bank analyst, lowering forecasts for the company's revenue and earnings.

Photo: Simon Fals

Danish Jyske Bank reduces its 2022 revenue and earnings estimates for Novo Nordisk by a respective 3.1 and 4.8 percent as a consequence of China's healthcare reform efforts to keep costs down, writes Chief Analyst at Jyske Bank Henrik Hallengreen Laustsen. The analyst has the recommendation "hold" with a share price target of DKK 645 for Novo Nordisk.

Medicine prices have been a recurrent theme recently, particularly in the US. China has also jumped on the bandwagon by introducing volume-based procurement (VBP) with a sixth round including insulin, which will affect prices, the bank says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs